Ambos NBGO assisted ThromboGenics in its auction procedure and subsequent signing of its Commercialization/Licensing Agreement for Ocriplasmin with Alcon/Novartis for Europe and non-US Rest-of-World

Ambos NBGO has assisted ThromboGenics with the preparation and organization of its auction procedure and with the subsequent preparation, negotiation and execution of the Commercialization/Licensing Agreement entered into with Alcon/Novartis for the product Ocriplasmin. This licensing agreement covers Europe and all other countries worldwide except the USA ( and 

ThromboGenics NV, a Belgian listed biopharmaceutical company (Euronext Brussels: THR) focuses on developing innovative ophthalmic medicines.  ThromboGenics is headquartered in Leuven, Belgium.  ThromboGenics lead product, Ocriplasmin, has successfully completed several clinical trials for the pharmacological treatment of symptomatic vitreomacular adhesion (VMA) (for more information about Ocriplasmin, see

Alcon, the global leader in eye care, provides innovative products that enhance quality for life by helping people worldwide see better.  Alcon is the second largest division of the Novartis Group with pro-forma sales of USD 10 billion in 2011.  Alcon is headquartered in Fort Worth, Texas, USA.

Ambos NBGO is an independent, full service Belgian law firm with offices in Brussels, Antwerp, Ghent and Zeebruges.  Ambos NBGO provides top level corporate, commercial and IP/IT expertise combined with an in-depth industry focus. Typical industries served by Ambos NBGO are the following:  Automotive, Biotechnology, New Energy, Financial Services, Real Estate, Corporate Governance and Technology (see also and    

For further details on this transaction, we refer to

Any information included in this news flash is communicated with the consent and approval of ThromboGenics. 

The AMBOS team was led by Kathleen Paisley, who co-chairs the firm's  IP team, and Roel Nieuwdorp, who is co-head of the corporate team, both of who are located in the firm's Brussels office.  For further information about this transaction, please contact Kathleen Paisley or Roel Nieuwdorp.

Published in: Press releases